辉瑞的争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 14 条
2024
2023
2022
辉瑞就涉嫌商业秘密盗用提起诉讼
提起诉讼
辉瑞在康涅狄格州地区法院起诉前员工Xiayang Qiu、Min Zhong等人。诉状指称Qiu和Zhong盗取辉瑞的商业秘密和机密信息,之后将其用于Regor;这些内容属于诉状中的指控。
Pfizer在康涅狄格州地区法院起诉前员工Xiayang Qiu、Min Zhong等人。诉状指称Qiu和Zhong盗取辉瑞的商业秘密和机密信息,之后将其用于Regor;这些内容属于诉状中的指控。
来源摘录
Pfizer Inc. filed suit on Wednesday in the District of Connecticut against defendants Regor Therapeutics Inc., Qilu Regor Therapeutics Inc., Xiayang Qiu, Min Zhong, and more.
The complaint alleges that Qiu and Zhong, both former employees of the plaintiff, stole trade secrets and valuable information from Pfizer that they later illegally incorporated into a new company, Regor.
2021
辉瑞等原告就 Ibrance 专利起诉齐鲁
提起诉讼
辉瑞及共同原告在特拉华州地区法院对齐鲁提起诉讼,请求法院宣告专利侵权并下令禁止进一步侵权。该诉讼涉及 Ibrance 的专利。侵权主张属于诉讼中的指控,尚未经认定。起诉日期为2021年6月29日。
Pfizer 及共同原告在特拉华州地区法院起诉 Qilu,要求法院宣告专利侵权并下令禁止进一步侵权。诉讼涉及 Ibrance 的专利;侵权主张属于诉讼中的指控。
来源摘录
The plaintiffs are seeking a declaratory judgement of patent infringement and an order enjoining Qilu from further infringement. The case concerns the patent for Ibrance, used to treat breast cancer.
Pfizer, Inc. (Pfizer), Warner-Lambert Company LLC, and PF Prison IMB B.V. filed suit on Tuesday against Qilu Pharmaceutical Co., LTD, and Qilu Pharma, Inc. (Qilu) in the District of Delaware.
2021
辉瑞就帕博西尼专利起诉MSN Pharmaceuticals
提起诉讼
辉瑞对MSN Pharmaceuticals提起诉讼,指称MSN拟生产的帕博西尼仿制药将侵犯辉瑞的专利。来源将该侵权行为表述为一项指控,而非法院认定。该争议涉及MSN拟生产的仿制药产品及辉瑞涵盖帕博西尼的专利。来源材料中未报告法院对该案实体问题的裁决。
来源摘录
On Tuesday, pharmaceutical company Pfizer filed a lawsuit against fellow pharmaceuticals company MSN Pharmaceuticals Inc. for allegedly infringing on their drug patent.
The plaintiff stated that contrary to the claims made in the notice letter, the defendant’s generic version of the drug does directly infringe upon 3 claims within its patent and its relation to their brand name drug IBRANCE.
2021
辉瑞召回 Chantix 戒烟药物
宣布召回
2021年9月,辉瑞宣布召回其戒烟药物 Champix(亦称 Chantix)。根据该公告,被召回的产品含有会致癌的化学物质。该事件被报道为该公司的一次产品召回。来源声明称被召回药物含有致癌化学物质,辉瑞针对其 Champix(Chantix)戒烟药物宣布了此次召回。
来源摘录
Pfizer announced on Friday that they were recalling all the champix (aka chantix) drugs that are used to get over smoking because they contain chemicals that cause cancer.
2021
辉瑞将 Chantix 召回范围扩大至全部批次
宣布召回
辉瑞将 Chantix 的召回范围扩大至全部 156 个 0.5 毫克和 1 毫克片剂批次。此次召回的原因是产品可能含有达到或超过 FDA 临时可接受摄入限值的亚硝胺杂质 N-Nitroso-varenicline。FDA 表示,长期摄入可能与理论上的癌症风险增加有关,同时指出患者不存在即时风险。
辉瑞将 Chantix 召回范围扩大至全部 156 个 0.5 毫克和 1 毫克片剂批次,原因是产品可能含有达到或超过 FDA 临时可接受摄入限值的亚硝胺杂质 N-Nitroso-varenicline。FDA 表示,长期摄入可能与理论上的癌症风险增加有关,但患者不存在即时风险。
品牌回应
整改 — Pfizer
Pfizer said it is undertaking this precautionary measure as alternative suppliers have been approved in the U.S.
来源摘录
The current recall involves all (156) lots of Chantix 0.5 mg and 1 mg tablets.
T*hey were distributed to wholesalers and distributors across the U.S., US Virgin Islands and Puerto Rico from May 2019 to September 2021.
The company is yet to receive any reports of adverse events assessed to be related to this recall.
2021
辉瑞就前员工涉嫌下载文件提起诉讼
提起诉讼
辉瑞起诉前员工Chun Xiao Li,指称她未经许可将数千份公司文件(包括机密信息和商业秘密)下载至个人设备。辉瑞申请临时限制令及禁令救济。
品牌回应
调查 — Pfizer
Pfizer told NBC 7 in a statement that the company is still investigating and pursuing civil action against an employee who it believes improperly downloaded thousands of documents before a planned exit from the company.
来源摘录
Pfizer told NBC 7 in a statement that the company is still investigating and pursuing civil action against an employee who it believes improperly downloaded thousands of documents before a planned exit from the company.
Trade SecretsThe pharmaceutical giant is suing Li for misappropriation of trade secrets in violation of the Defend Trade Secrets Act of 2016 and the California Uniform Trade Secrets Act; breach of contract; conversion; and trespass to chattel.
Pharmaceutical and biotechnology company Pfizer has sued a former employee for breaching her confidentiality agreement when she allegedly downloaded thousands of the company’s files, some of which contained trade secrets and confidential information, to her personal devices and attempted to “cover her tracks.”
2021
法官暂时禁止辉瑞员工使用商业秘密
裁决
在2021年涉及辉瑞的一项法律进展中,一名美国联邦地区法官暂时禁止Chun Xiao Li使用该公司的商业秘密。法官还授权辉瑞的律师检查她可能存储这些商业秘密的账户和设备。该命令属于临时性质,现有来源材料未说明进一步结果、其他当事方或所涉商业秘密的具体内容。本条目仅依据现有摘要和来源信息记录该事件。
来源摘录
In an order late on Tuesday, U.S. District Judge Cathy Ann Bencivengo temporarily blocked Li from using Pfizer's trade secrets, and said the company's lawyers can review accounts and devices where she might have stored them.
2021
辉瑞因潜在杂质风险召回部分Chantix批次
宣布召回
辉瑞在美国召回12个批次的Chantix,原因是这些产品可能含有超过公司可接受每日摄入限值的N-亚硝基伐尼克兰。报道指出,长期大量摄入可能导致癌症;辉瑞表示患者没有即时风险,并建议用户向医疗服务提供者或药房咨询更换事宜。
品牌回应
澄清 — Pfizer
There is no immediate risk to patients taking this medication
来源摘录
Pfizer voluntary re-called its smoking cessation drug Chantix because it contains a chemical that may cause cancer.
The company says the possible substance was detected in 12 lots at levels above the company’s established acceptable daily intake.
Pfizer has not received any reports of adverse events that have been related to this recall to date.
2021
辉瑞召回12批已流通的畅沛(Chantix)
宣布召回
辉瑞召回了另外12批已分销至美国和波多黎各批发商的畅沛(Chantix);这些批次的亚硝胺含量高于公司可接受的每日摄入量标准。
品牌回应
召回 — Pfizer
The July 16 recall, however, includes 12 more lots of the drug, which were already distributed to wholesalers in the U.S. and Puerto Rico between June 2019 and June 2021.
澄清 — Pfizer
'Patients currently taking Chantix should consult with their doctor to confirm if they received an affected lot, and if appropriate, about alternative treatment options,' the company said
来源摘录
The impacted lots contain levels of carcinogenic chemicals, called nitrosamines, that are above the company's own acceptable daily intake level
The July 16 recall, however, includes 12 more lots of the drug, which were already distributed to wholesalers in the U.S. and Puerto Rico between June 2019 and June 2021.
Pfizer has expanded its voluntary recall of smoking cessation drug varenicline (Chantix) to 12 lots at the consumer level, according to an update posted on the US Food and Drug Administration (FDA) website.
2020
辉瑞回应新冠疫苗合作排除中国市场的争议
公司回应
辉瑞就将其与BioNTech的疫苗合作排除中国市场一事引发的争议作出回应。辉瑞表示,该合作不包括中国市场,是因为BioNTech此前已与复星医药合作开发中国市场。辉瑞称仍在努力解决合作细节,并致力于为中国及全球患者提供药物和疫苗。
辉瑞表示,其与BioNTech的合作不包括中国市场,是因为BioNTech此前已与复星医药合作开发中国市场。辉瑞称仍在努力解决合作细节,并致力于为中国及全球患者提供药物和疫苗。
当事方说明的目的. 如果合作研发出安全有效的疫苗,确保全球范围内获得疫苗。
品牌回应
澄清 — 辉瑞
辉瑞在声明中表示,如果辉瑞与BioNTech的合作最终创造出一种安全有效的疫苗,其目的和意图是确保全球范围内获得疫苗。
来源摘录
辉瑞在声明中表示,如果辉瑞与BioNTech的合作最终创造出一种安全有效的疫苗,其目的和意图是确保全球范围内获得疫苗。鉴于形势的严峻性以及COVID-19在全球的蔓延速度,我们仍在努力解决细节问题,我们致力于为中国以及全球的患者提供获得优质药物和疫苗的机会。
3月19日,辉瑞生物制药集团(以下简称辉瑞)在官网发布声明称,近日,辉瑞公司和BioNTech SE宣布,两家公司已就共同开发和分销一种潜在的基于mRNA的冠状病毒疫苗达成意向书,以预防COVID-19感染。在此之前,BioNTech已宣布与复星医药合作开发中国市场。因此,辉瑞与BioNTech的协议不包括中国市场。
2009
2006
Torcetrapib临床安全性失败
辉瑞在III期试验报告接受torcetrapib方案的参与者死亡人数高于预期后,停止了torcetrapib的开发。该事件导致项目终止,并重新引起对心血管药物安全性监测的关注。